In a landmark development for healthcare accessibility, Akums Pharmaceuticals has introduced the first indigenous hydroxyurea oral solution for the treatment of sickle cell disease in children. Priced at an astonishingly low INR 600, the drug represents a mere 1% of the cost of the global standard, marking a significant step towards addressing the healthcare needs of underserved populations.
Traditionally, the import price for the global brand of Hydroxyurea solution stands at approximately Rs. 77,000, requiring stringent storage conditions at 2-8 Celsius. Akums Pharmaceuticals’ commitment to affordability and accessibility has led to the development of a solution that not only offers cost-effectiveness but also eliminates the need for refrigerated storage, ensuring room temperature stability.
Sickle cell disease, a genetic blood disorder prevalent in India’s tribal communities, presents significant health challenges such as anaemia, pain, and organ dysfunction. While the condition remains incurable, appropriate medication can effectively manage its symptoms, improving the quality of life for affected individuals.
The launch of Akums’ hydroxyurea oral solution aligns closely with the government’s Sickle Cell Anemia Elimination Mission, which aims to combat the disease through preventive measures and affordable treatment options. By offering a medication that enhances oxygen transport and maintains normal red blood cell shapes, the company contributes to improved health outcomes for those affected by sickle cell disease.
Union Health Minister Mansukh Mandaviya has praised the initiative, highlighting its importance for tribal communities and reaffirming the government’s commitment to eradicating sickle cell disease. The affordability and stability of the drug signify a significant step towards achieving equitable healthcare access and advancing India’s public health agenda.
As Akums Pharmaceuticals continues its dedication to addressing critical healthcare needs, the launch of the hydroxyurea oral solution underscores the pivotal role of innovation, affordability, and accessibility in combating genetic disorders and enhancing patient outcomes nationwid
